iBio (IBIO) Competitors $0.85 +0.00 (+0.53%) Closing price 04:00 PM EasternExtended Trading$0.85 +0.00 (+0.35%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBIO vs. NRXP, DTIL, ANL, ALGS, GNTA, ACRV, IMMX, DRRX, ELYM, and BRNSShould you be buying iBio stock or one of its competitors? The main competitors of iBio include NRx Pharmaceuticals (NRXP), Precision BioSciences (DTIL), Adlai Nortye (ANL), Aligos Therapeutics (ALGS), Genenta Science (GNTA), Acrivon Therapeutics (ACRV), Immix Biopharma (IMMX), DURECT (DRRX), Eliem Therapeutics (ELYM), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors NRx Pharmaceuticals Precision BioSciences Adlai Nortye Aligos Therapeutics Genenta Science Acrivon Therapeutics Immix Biopharma DURECT Eliem Therapeutics Barinthus Biotherapeutics NRx Pharmaceuticals (NASDAQ:NRXP) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Which has stronger valuation and earnings, NRXP or IBIO? iBio has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$25.13M-$2.24-1.42iBio$400K43.04-$24.91M-$1.74-0.49 Is NRXP or IBIO more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -550.94% iBio N/A -73.15%-45.51% Which has more risk and volatility, NRXP or IBIO? NRx Pharmaceuticals has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, iBio has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Does the media refer more to NRXP or IBIO? In the previous week, NRx Pharmaceuticals and NRx Pharmaceuticals both had 4 articles in the media. NRx Pharmaceuticals' average media sentiment score of 0.46 beat iBio's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NRXP or IBIO? NRx Pharmaceuticals currently has a consensus target price of $34.50, indicating a potential upside of 984.91%. iBio has a consensus target price of $3.50, indicating a potential upside of 311.76%. Given NRx Pharmaceuticals' higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in NRXP or IBIO? 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 19.0% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryNRx Pharmaceuticals and iBio tied by winning 7 of the 14 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$17.22M$1.01B$6.11B$21.78BDividend YieldN/A4.84%5.73%3.62%P/E Ratio-0.491.2584.5232.40Price / Sales43.0429.97609.4560.38Price / CashN/A17.6337.1624.37Price / Book0.608.0312.244.59Net Income-$24.91M-$7.71M$3.32B$1.01B7 Day Performance7.42%-0.46%0.76%1.25%1 Month Performance0.84%26.09%8.03%-0.58%1 Year Performance-70.18%-11.66%71.13%10.47% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio2.0694 of 5 stars$0.85+0.5%$3.50+311.8%-70.3%$17.22M$400K-0.49100News CoverageAnalyst ForecastNRXPNRx Pharmaceuticals3.0065 of 5 stars$3.35+2.4%$34.50+929.9%+147.2%$64.78MN/A-1.502News CoverageAnalyst ForecastDTILPrecision BioSciences3.7138 of 5 stars$5.67+4.2%$47.00+728.9%-26.3%$64.12M$68.70M-0.64200ANLAdlai Nortye1.2379 of 5 stars$1.76+1.7%$9.00+411.7%-16.9%$63.84M$5M0.00127Short Interest ↑Gap UpALGSAligos Therapeutics3.8965 of 5 stars$10.22+1.5%$50.00+389.2%+42.4%$61.94M$3.94M-0.5290News CoverageGNTAGenenta Science0.9528 of 5 stars$3.22-2.4%N/A-43.2%$60.36MN/A0.007Gap DownACRVAcrivon Therapeutics3.2502 of 5 stars$1.91flat$15.00+685.3%-75.9%$60.08MN/A-0.8558Positive NewsIMMXImmix Biopharma3.3174 of 5 stars$2.24+8.7%$8.00+257.1%+87.5%$59.40MN/A-2.919Positive NewsGap UpHigh Trading VolumeDRRXDURECTN/A$1.91flatN/AN/A$59.31M$1.66M-19.1080ELYMEliem TherapeuticsN/A$1.98-2.9%N/A-64.3%$58.91MN/A-3.749Gap UpHigh Trading VolumeBRNSBarinthus Biotherapeutics2.0997 of 5 stars$1.57+8.6%$3.00+91.1%+12.5%$58.85M$14.97M-0.91107Analyst ForecastShort Interest ↑Gap Down Related Companies and Tools Related Companies NRXP Alternatives DTIL Alternatives ANL Alternatives ALGS Alternatives GNTA Alternatives ACRV Alternatives IMMX Alternatives DRRX Alternatives ELYM Alternatives BRNS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
